Hangzhou Haoyue Personal C (605009.SS) traded flat 0 % during a 24 hours period ending at 04:42 PM Central Europe on Monday 26th. One Hangzhou Haoyue Personal C stock can currently be bought for about CNY 25.18 on popular exchanges. Current supply of Hangzhou Haoyue Personal C stocks is 213.9 mn. Hangzhou Haoyue Personal C has a current market capitalization of CNY 5.3 bn and approximately CNY 28 mn worth of Hangzhou Haoyue Personal C was traded on exchanges in the last 24 hours. Since last month end, Hangzhou Haoyue Personal C has traded -0.96 % down. Simple moving average of last 200 days is at CNY 24.23. The highest price of past 52 weeks was recorded at CNY 35.18 on 11/19/2025. 52 weeks low was at CNY 21.37 on 06/25/2026.
Here is how related stocks have performed in the past 24 hours:
Suzhou Highfine Biotech (301393.SZ) traded flat 0 % and now trades at CNY 56.68. Suzhou Highfine Biotech has a market capitalisation of CNY 6.3 bn. Current price/earnings ratio for Suzhou Highfine Biotech is 57.44.
Xiamen Wanli Stone Stock C (002785.SZ) traded flat 0 % and now trades at CNY 28.17. Xiamen Wanli Stone Stock C has a market capitalisation of CNY 6.3 bn. Xi’an Wanli Stone Stock Co., Ltd. reported its first‑quarter results for the year. Revenue for the quarter fell, while profit attributable to shareholders rose markedly. Over the full year to date, total revenue also declined, yet the company’s net profit increased significantly, driven in part by lower financial costs and higher investment income. Operating cash flow showed a strong positive swing, largely from higher cash received from sales and lower cash paid for goods. The company’s equity base grew modestly, and basic earnings per share reflected the profit improvement. Overall, the results suggest a resilient profitability profile amid a challenging revenue environment.
Beijing Sun-novo Pharmaceu (688621.SS) traded flat 0 % and now trades at CNY 54.58. Beijing Sun-novo Pharmaceu has a market capitalisation of CNY 6.3 bn. Beijing Sun-novo Pharmaceu has a current price to earnings ratio of 161.3. A recent release of third‑quarter holdings from several prominent Chinese funds highlights a mixed reaction to the broader market environment. Several managers have shifted focus from high‑growth technology stocks toward more stable sectors, such as utilities, energy, and healthcare. This realignment comes after a period of significant pullback in the technology and AI segments. At the same time, some funds have increased exposure to leading companies in the AI and semiconductor fields, reflecting a belief that these areas will recover in the medium term. The changes illustrate a strategic balance between defensive positioning and opportunistic investment in sectors that may rebound, while also maintaining a core emphasis on sectors with resilient cash flow and lower valuation compression.
Chengdu Kanghua Biological (300841.SZ) traded flat 0 % and now trades at CNY 48.81. Current market capitalisation for Chengdu Kanghua Biological is CNY 6.3 bn. Current price/earnings ratio for Chengdu Kanghua Biological is 26.78.
Jin Tong Ling (300091.SZ) traded flat 0 % and now trades at CNY 2.15. Current market capitalisation for Jin Tong Ling is CNY 6.3 bn.
About Hangzhou Haoyue Personal C
Hangzhou Haoyue Personal Care Co., Ltd is a company based in China that specializes in the manufacturing and distribution of sanitary paper products. The company produces and sells baby diapers, adult diapers, sanitary napkins, and other related products. Hangzhou Haoyue Personal Care markets its products worldwide. You can find more information about the company on its website at www.hz-haoyue.com . The company’s stock is traded on the Shanghai Stock Exchange.
